Expert Insights: CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia – Clinical Updates and Innovations
Release Date: January 15, 2020
Watch the experts in this stimulating and informative conversation about CAR T-cell therapy.
The target audience for this symposium is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.
After completing this activity, participants should be better able to:
- Discuss clinical trial data of CAR T-cell-based therapies for the treatment of patients with hematologic malignancies, and how these therapies fit within the treatment landscape
- Evaluate emerging clinical data and novel approaches to CAR T-cell therapy
- Identify characteristics of patients who are appropriate for treatment with CAR T-cell therapy
- Review approaches to mitigate adverse events that may be encountered with the use of CAR T-cell therapy
- Explore areas of investigation in CAR T-cell therapy performance and innovative design approaches
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Materials will be available online through January 15, 2021.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Conference Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below:
All disclosed conflicts of interest have been resolved by independent content review.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
Julie Vose, MD, MBA - Chair
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology, Department of Internal Medicine
University of Nebraska Medical Center
Grants/Research Funding: Acerta Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Kite Pharma, Merck, Novartis, Seattle Genetics, Inc.
Consultant, Honoraria: AbbVie, Epizyme, Karyopharm
David Siegel, MD, PhD
Division Chief, Myeloma
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey
Consultant, Board of Directors (Membership)/Advisory Committee, Research Funding, Speakers’ Bureau: Amgen Inc.,
Bristol-Myers Squibb Company, Celgene Corporation, Janssen, Takeda
This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
This activity is supported by independent educational grants from Legend Biotech and Novartis Pharmaceuticals Corporation.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.